BXP — Beximco Pharmaceuticals Share Price
Last trade - 00:00- £171.75m
- £222.74m
- BDT44.39bn
- 97
- 98
- 73
- 99
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 3.34 | ||
| PEG Ratio (f) | 0.19 | ||
| EPS Growth (f) | 21.45% | ||
| Dividend Yield (f) | 8.69% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.52 | ||
| Price to Tang. Book | 0.58 | ||
| Price to Free Cashflow | 4.74 | ||
| Price to Sales | 0.57 | ||
| EV to EBITDA | 2.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.48% | ||
| Return on Equity | 12.56% | ||
| Operating Margin | 19.86% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | BDTm | 25,611.95 | 29,493.57 | 34,669.17 | 39,266.66 | 44,391.6 | 50,264.48 | 56,909.81 | 14.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +16.76 | +45.16 | +0.34 | -10.72 | +26.35 | +15.64 | +25.83 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beximco Pharmaceuticals Limited is a Bangladesh-based company which is a manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The Company is engaged in manufacturing and marketing of generic pharmaceutical formulation products covering a range of therapeutic categories. It offers products in different dosage forms, including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable and Large Volume Intravenous Fluids. Besides formulation products, the Company also manufactures APIs and renders contract manufacturing services to other companies. Products of the Company are sold in domestic and international markets. The subsidiaries of the Company include Nuvista Pharma Limited (NPL), Synovia Pharma PLC (SPP), Beximco Pharma API Limited (BPAL).
Directors
- Ahmed Rahman CHM
- Nazmul Hassan CEO
- Ahmed Rahman VCH
- Ali Nawaz CFO
- Rabbur Reza COO
- Jamal Choudhury GMG
- Zakaria Chowdhury DSL
- Osman Chowdhury OTH
- Afsar Ahmed OTH
- Abdur Rahman OTH
- Lutfur Rahman OTH
- Mohd. Tahir Siddique OTH
- Md. Asad Ullah SEC
- Iqbal Ahmed DRC
- Mohammad Qasem DRC
- Abu Bakar Siddiqur Rahman DRC
- Quamrun Ahmed NED (61)
- Reem Shamsuddoha NED (32)
- Ibraheem Hosein Khan IND
- Abdul Khan IND
- Mamtaz Uddin Ahmed NID (62)
- Mahbubul Alam NID (79)
- Abdur Rahman Khan NID (87)
- Last Annual
- June 30th, 2024
- Last Interim
- September 30th, 2024
- Incorporated
- December 31st, 1976
- Public Since
- October 21st, 2005
- No. of Shareholders
- 48,217
- No. of Employees
- 1,122
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 446,112,089
- Address
- 19 Dhanmondi R/A, Road No. 7, DHAKA, 1205
- Web
- https://www.beximcopharma.com/
- Phone
- +880 258611001
- Auditors
- M.J.Abedin & Co.
Latest News for BXP
Upcoming Events for BXP
Similar to BXP
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
BSF Enterprise
London Stock Exchange
Celadon Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 18:34 UTC, shares in Beximco Pharmaceuticals are trading at 38.50p. This share price information is delayed by 15 minutes.
Shares in Beximco Pharmaceuticals last closed at 38.50p and the price had moved by -3.75% over the past 365 days. In terms of relative price strength the Beximco Pharmaceuticals share price has underperformed the FTSE All Share Index by -10.43% over the past year.
The overall consensus recommendation for Beximco Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Beximco Pharmaceuticals dividend yield is 6.98% based on the trailing twelve month period.
Last year, Beximco Pharmaceuticals paid a total dividend of BDT4.00, and it currently has a trailing dividend yield of 6.98%. We do not have any data on when Beximco Pharmaceuticals is to next pay dividends.
We do not have data on when Beximco Pharmaceuticals is to next pay dividends. The historic dividend yield on Beximco Pharmaceuticals shares is currently 6.98%.
To buy shares in Beximco Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 38.50p, shares in Beximco Pharmaceuticals had a market capitalisation of £171.75m.
Here are the trading details for Beximco Pharmaceuticals:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: BXP
Based on an overall assessment of its quality, value and momentum Beximco Pharmaceuticals is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Beximco Pharmaceuticals is 153.68p. That is 299.18% above the last closing price of 38.50p.
Analysts covering Beximco Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of BDT15.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beximco Pharmaceuticals. Over the past six months, its share price has outperformed the FTSE All Share Index by +0.31%.
As of the last closing price of 38.50p, shares in Beximco Pharmaceuticals were trading +12.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Beximco Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 3.34. The shares last closed at 38.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Beximco Pharmaceuticals' management team is headed by:
- Ahmed Rahman - CHM
- Nazmul Hassan - CEO
- Ahmed Rahman - VCH
- Ali Nawaz - CFO
- Rabbur Reza - COO
- Jamal Choudhury - GMG
- Zakaria Chowdhury - DSL
- Osman Chowdhury - OTH
- Afsar Ahmed - OTH
- Abdur Rahman - OTH
- Lutfur Rahman - OTH
- Mohd. Tahir Siddique - OTH
- Md. Asad Ullah - SEC
- Iqbal Ahmed - DRC
- Mohammad Qasem - DRC
- Abu Bakar Siddiqur Rahman - DRC
- Quamrun Ahmed - NED
- Reem Shamsuddoha - NED
- Ibraheem Hosein Khan - IND
- Abdul Khan - IND
- Mamtaz Uddin Ahmed - NID
- Mahbubul Alam - NID
- Abdur Rahman Khan - NID